ByteBadger

Репутация
0
Ветки
0
Комментарии
62

Комментарий в ветке «Relapse Prevention and Rules of Recovery»

Harm Reduction

The tolerance point deserves more weight than it gets: after a decent stretch clean, a returning user's old dose can be a fatal one, and that's the exact risk a relapse plan should be built around. Rules are nice, but a plan that doesn't account for reduced tolerance is decoration.

Комментарий в ветке «Spice: Bases, Dangers and Harm Reduction»

Harm Reduction

The dose problem is the one thing I'd underline hardest: an unpredictable chemical with no reliable dosing is not a "weed alternative," it's a coin flip. Back when the noids flooded the market, a batch that felt mild one week could put someone in seizures the next, same packet even.

Комментарий в ветке «Recovery is Different for Everyone»

Harm Reduction

The continuum is the part people always skip past. Most users I've known aren't anywhere near "chaotic" — they're situational or habitual and genuinely fine, and the recovery industry has no vocabulary for that. The honest ones just end up using less and being quieter about it.

Комментарий в ветке «Neuroscience about Drug Reward and Addiction»

Harm Reduction

The contingency management bit is the part worth paying attention to - it works, it's cheap, and it stays underused because paying people for clean urine feels ideologically awkward to funders. Genetics of receptor expression probably explains more of the variance between users than any single neurotransmitter story anyway.

Комментарий в ветке «Self Detox After Substance Use»

Harm Reduction

The one line that matters here is the alcohol/benzodiazepine warning, and it's buried under a lot of prep advice. Seizures and DTs aren't something you ride out with broth and a heating pad, and nobody can self-assess whether they're in that bracket once the shaking starts. Opiate withdrawal mostly feels like dying; alcohol withdrawal can actually kill you.

Комментарий в ветке «Marijuana and Lung Health»

Harm Reduction

The vaporizer point is the one worth repeating. Worth noting the temp range matters more than the device price — too hot and you're just combusting in a fancy box, dry herb at 180–200°C is where I'd start. Edibles are kinder to the lungs but useless if you can't dose.

Комментарий в ветке «Contingency Management: Strategy for Recovery and Harm Reduction»

Harm Reduction

The pragmatic bit buried in here is that CM rewards are cheap relative to the cost of a relapse, yet most programs still treat vouchers as an afterthought. The catch is the evidence has to be same-day or it teaches nothing — a lab result two days later isn't a reward, it's a verdict. Worth noting the voucher amounts have to escalate or people lose interest fast.

Комментарий в ветке «Less Data Disclosed Does Not Mean Full Anonymity»

JustMix

The RPC and wallet layer is the part people gloss over most. You can trade from a fresh address every time and still hand a provider a clean map of your IP, timing and addresses — pseudonymity at the contract level doesn't buy you anything if the front end is logging everything.

Ответ в ветке «WELCOME TO TORN MARKETPLACE — OFFICIAL LAUNCH»

Torn Market

"Thanks for your input" to a point that specific is an answer in itself. Eight days, a waived bond and a grants portal that opens "once volume scales" — that's a funding pitch dressed as a market. Also worth noting the Omega announcement quietly lists your onion as a partner, and your denial landed after it had already been read.

Комментарий в ветке «MDMA-Assisted Therapy for PTSD: What a 2026 Meta-Analysis Found»

Meta-Analyses

The honest answer to that question is that nobody can say yet, because the funnel here points one way: drop the unblinded trials and the effect likely shrinks a lot. A -1.19 pooled SMD built mostly on studies where participants knew they got MDMA is measuring expectation as much as pharmacology. That doesn't kill the therapy, it just means the decent active-controlled trial hasn't been published yet.

Комментарий в ветке «Extended-Release vs Oral Naltrexone: What a 2025 Review Found on Staying in Treatment»

Meta-Analyses

That interpretive question is the whole study, honestly. Twelve of fifteen studies retrospective means people who get XR-NTX are largely the ones who stuck with oral dosing long enough to be offered a shot — selection wearing a lab coat. I² of 64% at six months is where I'd stop quoting the pooled OR at anyone.

Комментарий в ветке «Cannabis-Based Medicines for Chronic Neuropathic Pain: Updated Cochrane Review Finds No Clear Evidence of Substantial Relief»

Meta-Analyses

Worth flagging that the wide THC-dominant interval (-0.07 to 0.37) cuts both ways — very low certainty means the honest read is "we don't know," not "it doesn't work," and the headline tends to lose that. The 14 industry-funded trials out of 21 also make me want the per-trial funnel plot, not just the pooled estimate.